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ABSTRACT
Objective:We investigated possible correlations between latent cervical human papillomavirus infec-
tion (CHPI) and other sexually transmitted diseases (STDs).
Methods: Of 972 randomly selected women attending 2 family planning clinics and a youth clinic
who had agreed to participate in a study concerning STDs, 66 (6.8%) had latent CHPI.
Results: An association was found between latent CHPI on one hand and a history of genital
chlamydial infection, gonorrhea, recurrent vaginal candidiasis, cervicitis, or pelvic inflammatory
disease (PID) on the other, while no correlation between latent CHPI and coexistent STDs was
found. No correlation of latentCHPI to either current or past genital warts was noted. In multifac-
torial analyses, which included the lifetime number of sexual partners and age at first intercourse,
we found that all significant associations except a history ofgonorrhea vanished.
Conclusions: In this study population, screening for other current STDs in women with latent
CHPI would be oflimited value. (C) 1995 Wiley-Liss, Inc.
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enital warts are mainly caused by infection
with human papillomavirus (HPV) types 6
and 11, while cervical human papillomavirus in-
fection (CHPI) is mainly caused by HPV types 16,
18, 31, 33, and 35.
It has been speculated that the presence of a
coexistent infection of the genital epithelium in-
creases the susceptibility to HPV or that a coexist-
ent sexually transmitted disease (STD) can activate
a latent CHPI. Indirect evidence of a correlation
between latent CHPI and STDs is the high preva-
lence of latent CHPI in STD clinic patients
2-4
compared with the general population, with an es-
timated prevalence of 6-12%. s’6 Although a his-
tory of STD is common in latent CHPI patients,
7
less well established is whether a concurrent STD is
more frequent in latent CHPI patients.
The purpose of our study was to examine any
correlations between latent CHPI and the presence
or a history of STDs, i.e., Chlamydia trachomatis,
Neisseria gonorrhoeae, genital herpes, or genital
warts. Furthermore, we sought correlations of cur-
rent latent CHPI and previously diagnosed cervi-
citis, pelvic inflammatory disease (PID), or recur-
rent genital candidiasis.
MATERIALS AND METHODS
Between November 1989 and January 1991, 3-4
women per day were enrolled in the study at the
family planning clinics at Eskilstuna and Danderyd
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Hospitals (Stockholm) and at the youth clinic in
Eskilstuna. Eskilstuna is a town of 90,000 inhabit-
ants located 110 km southwest of the capital city,
Stockholm (1.5 million inhabitants).
A selected number of midwives were trained for
the particular tasks involved in the study. Women
with predetermined positions on the outpatient list
were asked by midwives if they would like to par-
ticipate in the study. The midwives were not in-
volved in the patient scheduling, so the identities of
the participants were unknown to the midwives.
The participants were added to the outpatient list
consecutively when they booked a time so as to
avoid selection bias.
The midwives conducted the structured personal
interviews and collected the laboratory samples.
The information on previous STDs and genital
infections was checked in the original patient
records to avoid memory bias.
Of the 1,077 women who were asked, 1,011
(93.9%) agreed to participate. This high participa-
tion rate likely reflects a great interest in the study
design, which offered the detection of STDs and
other gynecologic infections. HPV screening was
performed in all women but the first 39 (3.9%)
women who were enrolled at the beginning of the
study before the test reagents became available.
Thus, 972 women were available for analysis. The
906 women with negative HPV tests made up a
comparison group (COMP).
Occasionally, there were some missing values
that rarely exceeded 1% of the study population.
These are not included in the tables.
No economic compensation was offered to the
participating women. The anonymity of the partic-
ipants was guaranteed to ensure as honest answers as
possible. No identifying details were included in
either the patient record forms or computerized
data. Only the authors had access to the patient
codes.
In all participants, urethral and endocervical
specimens for the isolation of C. trachomatis were
collected with nontoxic, cotton-tipped swabs and
transported in a sucrose phosphate buffer (2-SP)
with 10% fetal calfserum. The cultures were grown
on cycloheximide-treated McCoy cells.
8 Direct im-
munofluorescenc using labeled monoclonals (Mi-
cro Track, SYVA, San Jose, CA) were also used in
all women for the detection of C. trachomatis inclu-
sions. The cervical samples for enzyme immunoas-
say were collected by swabs provided by the kit
producer (Chlamydiazyme, Abbott, or Chlamydia
EIA, SYVA). Positive Chlamydiazyme tests were
confirmed by Abbott’s Chlamydia Confirmatory
Test.
9 A positive test with either method was re-
garded as proof of a genital chlamydial infection.
Urethral and endocervical specimens were collected
for the culture of N. gonorrhoeae, o For the detec-
tion of Trichomonas vaginalis, wet smear micros-
copy was performed. The cultures for yeast fungi
were made on Rogosa agar from swab samples from
the posterior vaginal fornix and analyzed by serum
tests for the distinction of Candida albicans. Sero-
logical screening tests for human immunodeficiency
virus (HIV) were made by two enzyme-linked im-
munosorbent assay (ELISA) methods: Wellcozyme
HIV-1 recombinant EIA (Wellcome Diagnostics,
Dartford, England) and Enzygnost anti HIV-1,2
EIA (Behringwerke AG, Marburg, Germany).
For the detection and typing of HPV DNA, a
cell sample was collected from the ectocervix by
means of a brush device (Cytobrush, Medscand,
Malm6, Sweden) and washed with ml of aqueous
lytic buffer (Oncor(R), Inc., Gaithersburg, MD) in
a 2-ml microfuge tube.
11 The tubes were mailed to
the laboratory at ambient temperature and stored at
4C until analyzed. The HPV typing was made by
Southern blot. Sodium dodecyl sulfate was added to
the specimens, after which they were digested with
proteinase K and incubated at 50C for 15 min.
Residual peptides were salted out by adding a "pro-
tein precipitating agent" (Oncor(R)) retaining the
supernatant. After vortexing and centrifugation,
the DNA was precipitated from this supernatant
with 3 volumes of ethanol at room temperature.
After careful washings twice with ethanol, the prep-
arations with resultant DNA pellets were dissolved
overnight at 52C using Tris-EDTA buffer. After
digestion with 2 restriction enzymes (Bam H and
Pst 1) and electrophoresis in 1% agarose gel, the
separated DNA fragments were first depyrinated
with hydrochloric acid and then denatured with
sodium hydroxide. The blotting onto a nylon mem-
brane was accomplished with limited vacuum using
the Probe Tech electrophoresis and transfer equip-
ment (Oncor(R)). The hybridization was then per-
formed using a mixture of subgenomic probes se-
lected to label only one band of a defined size for
each of the HPV types studied (Oncor Human
Papillomavirus Typing System(R)). The cases with
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TABLE I. Distribution of age among women with
latent CHPI and a comparison group (COMP)*
Latent CHPI (%) COMP (%)
Age (years) (N 66) (N 905)
15-20 15 (22.7) 151 (16.7)
20-24 26 (39.4) 331 (36.6)
25-29 12 (I 8.2) 201 (22.2)
30-34 9 (I 3.6) 104 (I 1.5)
35-39 (I.5) 53 (5.9)
40-48 3 (4.6) 65 (7.2)
Total 66 (100.0) 905 100.
*P 0.35.
distinct bands, however unrelated to any of the
standards, were designated as unknown types.
The samples were obtained in the following or-
der: general culture, gonorrhea culture, chlamydia
culture, Chlamydiazyme, and sample for I-IPV typ-
ing.
The results were computerized and analyzed with
the JMP statistical program.
12 The initial signifi-
cance tests were performed by chi-square for nom-
inal variables (Pearson and likelihood ratio) and
t-test for continuous variables. In order to adjust
for age differences and to assess the simultaneous
effect of more than one variable, we used multiway
frequency tables analyzed by means of logistic re-
gression (analysis of log likelihood) to identify and
check for possible confounding.
RESULTS
Sixty-six (6.8%) of the 972 women were positive
for one or more of the following I-IPV types: 4
HPV6, 4 I--IPV 11, 25 HPV 16, 10 HPV 18, 14
HPV31, 5 HPV33, 5 HPV 35, and 8 unknown
HPV types. Nine women had mixed HPV infec-
tions.
The mean age for the women with latent CHPI
was 24.5 years (SD 0.87), while it was 26.0 years
(SD 0.23) for the COMP group (P 0.10). The
age range was 15-48 years. The age distribution is
given in Table 1.
All women were sexually active, but partner
changes were significantly more frequent in ages
15-19 years (P 0), with 36% reporting 2 or
more sexual partners during the previous 6 months.
This frequency continuously decreased with every
5-year group to 7% of the women above 35 years of
age. The frequency of having had sex with a casual
partner during the previous month was signifi-
cantly different only among women in ages 30-34
years (1.6%, P 0.02). In the other age groups,
this figure varied from 5.4% (above 35 years) to
9.3% (25-29 years) (not shown in Table 1).
There were no I--IIV-positive women in the study.
Only one case of trichomoniasis (0.1%) was noted.
For genital chlamydial infection, gonorrhea,
genital warts, genital herpes, and vaginal candidia-
sis, the following 3 variables were detailed: history,
current infection, and the occurrence of more than
one episode of an infection (Table 2).
There were 83 (8.8%) chlamydia-positive
women. No significant difference was noted in the
prevalence between the latent CHPI and COMP
groups. A history of chlamydial infection was sig-
nificantly more frequent in the latent CHPI
(30.3%) than in the COMP (15.8%) group, but
no difference was noted between the 2 groups in a
history of more than one episode of chlamydial
infection (including the current episode).
Four percent of the study population reported
having previously had gonorrhea. Such a history
was noted significantly more often in women with
latent CHPI than in women in the COMP group
(P 0.006).
There were 39 cases of current genital warts in
the vagina, on the vulva, or in the perianal area,
equally distributed in the 2 groups of women, as
was also the case for a history of genital warts. In
95% of the cases, the diagnosis had been made by a
physician. Of the 8 cases who were current carriers
ofHPV types 6 and 11 in the cervix, 2 had current
genital warts, which was a significantly increased
frequency (P 0.003) compared with the women
in the COMP group, and had a history of genital
warts.
No difference between the latent CHPI and
COMP groups was noted with regard to genital
herpes.
A history of genital candidiasis was recorded in
372 women (38.3%), with no difference between
the latent CHPI andCOMP groups. Of those who
had such a history, the mean number of episodes
was significantly higher in the latent CHPI than in
theCOMP group. C. albicans was isolated from 71
(7.9%) of the 972 women (yeast cultures were not
performed in 67 women), with no significantly
different prevalence in the 2 groups of women
studied.
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TABLE 2. Occurrence of STDs and vulvovaginal candidiasis among women with latent CHPI and a comparison
group (COMP)
Latent CHPI (%) COMP (%)
(N 66) (N 906)
History of chlamydial infection 20 (30.3) 143 (15.8) 0.002
Current chlamydial infection 4 (6. I) 79 (9.0) 0.40
>1 episode of chlamydial infection 2 (3.0) 31 (3.4) 0.86
History of gonorrhea 7 (10.6) 33 (3.6) 0.006
Current gonorrhea 0 (0. I) 0.75
>1 episode of gonorrhea (I.5) 3 (0.3) 0.15
History of genital warts 4 (6. I) 69 (7.6) 0.63
> episode of genital warts (I.5) 9 (I.0) 0.42
Signs of genital warts 3 (4.6) 36 (4.0) 0.82
History of herpes 3 (4.6) 32 (3.5) 0.68
Mean no. of episodes of herpes 2.7 II.0 0.50
Signs of herpes 0 3 (0.3) 0.81
History of candidiasis 27 (40.9) 345 (38. I) 0.65
Mean no. of episodes of candidiasis 7.8 3.6 0.01
Signs of candidiasis 7 (I 2. I) 64 (7.6) 0.22
TABLE 3. History of cervicitis and any STD among women with latent CHPI and a comparison group (COMP)
Latent CHPI (%) COMP (%)
(N 66) (N 906)
History of PID 9 (I 3.6) 55 (6. I) 0.02
Medical treatment for PID 9 (100.0) 54 (98.2) 0.58
History of cervicitis (I 6.7) 69 (7.6) 0.01
Medical treatment for cervicitis 10 (90.9) 55 (80.9) 0.58
History of any STD 28 (42.4) 228 (25.2) 0.003
Cervical cytology (not shown in Table 2) with
changes suggestive of HPV infection or cervical
intraepithelial neoplasia was positive in 18 women,
of whom 9 were HPV negative. The inclusion of
these 9 women in the latent CHPI group made no
difference in the significance tests. However, the
frequency ofcurrent genital warts increased to 6.7%
and the frequency of current genital chlamydial
infection increased to 8.0% in the women in the
latent CI-IPI group. The corresponding values for
the COMP group were 3.8% and 8.7%, respec-
tively.
There was a significant difference with regard to
a history of any STD, i.e., genital chlamydial in-
fection, gonorrhea, genital warts, trichomoniasis,
or genital herpes, which was reported by 42% of
those in the latent CHPI group and 25% in the
COMP group (Table 3).
A history of cervicitis and PID was more than
twice as frequent among those with latent CHPI
than among those in the COMP group. In 17
(26.6%) of the 64 cases with a history of PID, the
diagnosis had been laparoscopically verified. There
was no difference between the 2 groups. In the
remaining cases, only clinical criteria had been used
to establish the diagnosis. Thirty-nine (59.1%) of
the patients with a PID history had received hospi-
tal care.
In the logistic regression analyses with adjust-
ment for age, age at first intercourse, and lifetime
number of sexual partners, we found a significant
correlation between latent CHPI and a history of
gonorrhoea, but not for chlamydial infection, which
vanished (P 0.03 and 0.12, respectively), as did
a history of any STD (P 0.12) and of recurrent
candidiasis (P 0.06). A history of both PID and
cervicitis lost its significance (P 0.09 and 0.10,
respectively) when a history of any STD was in-
cluded in the analyses.
DISCUSSION
A principal finding of our study was the lack of a
correlation between latent CHPI and coexistent
STDs, e.g., genital clarnydial infection and genital
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warts. Thus, in the population we studied, there
would have been no benefit in selecting women
with latent CHPI as a prescreening method for
other STDs or vice versa. Our results did not
support the theory of the ability of other STDs to
activate a latent CHPI or to make the genital mu-
cosa more susceptible for the acquisition ofHPV.
An unexpected finding was the lack of a signifi-
cant difference for the prevalence of latent CHPI
between ages, although the mean age for women
with latentCHPI was 1.5 years less than for women
in the COMP group. One reason for the relatively
low age difference between the 2 groups studied
might be the comparably high sexual activity
present in the older age groups.
The possibility that "STD core members" func-
tion as a reservoir has been used to support the
prospect of a relationship between latent CHPI and
other STDs.
13 The "core members" have been de-
fined as a group of males and females who harbor
specified STDs and, after treatment, often reinfect
each other. As a result, the frequency of the STDs
will not decrease in this population. Our study was
not able to define a single core group for the cur-
rent STDs that were studied.
The strong correlation in our study between a
current latent CHPI and a history of genital
chlamydial infection or gonorrhea has also been
found in other studies,
14,16 aS well as in 2 previous
studies
15,17 not reporting a correlation between la-
tent CI--IPI and coexistent chlamydial cervicitis.
Yliskoski and coworkers
18 found that a concomi-
tant cervicitis had no influence on the clinical course
of latent CHPI.
Both latent CHPI and genital chlamydial infec-
tion involve the squamous epithelium in the transi-
tional zone. It has been thought that ectopy facili-
tates the establishment ofboth infections. It remains
to be proved, however, that the same is true for
chlamydial infections.
19 In our study population, it
was not true for latent CHPI (unpublished re-
sults).
In our multifactorial analyses, only a history of
gonorrhea remained significant after the adjust-
ment for age, sexual behavior, and a history of any
STD. All other associations were only covariables
for sexual promiscuity, an expected result confirm-
ing that the STDs studied here have the same mode
of transmission. We have no explanation for why a
history of gonorrhea remained significant after ad-
justment. There might have been behavioral fac-
tors that we could not control for.
One current STD is a well-known risk factor for
other STDs.
13 An unexpected finding was the lack
of a significant association between latent CHPI
and current genital warts or between latent CHPI
and a history of genital warts. The diagnosis of
genital warts, often suspected by the woman her-
self, is usually clinically uncomplicated, although
suspected warts might represent other conditions,
mostly benign tumors. In this study, the disgnoses
were made by gynecologists, venereologists, or by
physicians of other specialities in 95% of the cases.
Our study confirmed an association of latent
CHPI with I-IPV types 6 and 11 and genital warts.
Moscicki and coworkers
is also found a relationship
between latent CHPI and genital warts. In their
study, 24% of the cases of latent CHPI were caused
by HPV types 6 and 11 compared with 12% in our
study. In those patients who were positive for HPV
types 6 and 11, genital warts were found in 58%,
whereas in those patients with other HPV types,
visible warts were noted in only 22%. Law and
coworkers
2 found no correlation between latent
CHPI and coexistent genital warts, which is in
contrast to still another study
21 reporting an associ-
ation between a history of genital warts and latent
CHPI. These contradicting results raise the ques-
tion of whether latent CHPI and genital warts,
despite being caused by the same virus, are not
more closely linked to each other than to other
STDs from an epidemiological and behavioral point
of view.
Although most studies on latent CHPI and gen-
ital warts have clearly demonstrated the dominance
of a sexually transmitted route,22’2 other transmis-
sion routes have been proposed, for instance, by
fomites. In a recent study, the habit of bathing in
hot tubs was strongly correlated after adjustment
for age and sexual risk behavior to the occurrence
24 of genital warts.
Both a history ofPID and a history of cervicitis
were associated with latent CHPI, but the signifi-
cance vanished after the adjustment for sexual vari-
ables and a history of any STD. Although this
finding indicates that sexual risk behavior is the
common denominator for these conditions, no con-
clusions can be drawn as to whether cervicitis or
PID predisposes a patient to latent CHPI or vice
versa. The clinical diagnosis of PID is difficult to
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establish with any degree of accuracy as, e.g., cer-
vicitis can mimic PID. However, both diseases
were noted to be markers for a subsequent risk of
acquiring latent CHPI.
Our study showed that, in the population re-
ported, a previous STD was a risk factor for cur-
rent latent CI--IPI, but provided no evidence of an
increased prevalence of coexistent STDs in women
with latent CHPI.
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